RT期刊文章SR电子T1潜在的长期随访的聚焦超声单边Subthalamotomy帕金森病摩根富林明神经病学神经学乔FD Lippincott Williams &威尔金斯SP e1395 OP e1405 10.1212 / WNL。半岛投注体育官网100签证官0000000000206771是13 A1劳尔Martinez-Fernandez A1 Elena Natera-Villalba A1 Jorge美国Manez米罗A1拉斐尔Rodriguez-Rojas A1玛塔玛尔塔德尔·阿拉莫A1何塞天使Pineda-Pardo A1克劳迪娅阿曼A1 Ignacio Obeso A1大卫Mata-Marin A1弗里达·赫尔南德斯·费尔南德斯A1卡门Gasca-Salas A1米歇尔Matarazzo A1费尔南多Alonso-Frech A1 Jose a Obeso年2023 UL //www.ebmtp.com/content/100/13/e1395.abstract AB背景和目标单边磁resonance-guided聚焦超声波subthalamotom半岛投注体育官网y (FUS-STN)已被证明改善帕金森病(PD)的基本运动特性。这种影响是否持续还不知道。本研究旨在报告PD患者的长期结果单边FUS-STN对待。方法:我们进行了一项前瞻性开放研究的不对称的PD患者接受单边FUS-STN。所有患者进行评估后36个月治疗。主要结果的差异从基线到36个月后FUS-STN得分的运动障碍Society-Unified帕金森病评定量表(MDS-UPDRS)电动机部分(III)的治疗hemibody off-medication状态。安全的结果包括所有不良事件发生在随访中。二次结果的变化MDS-UPDRS三世分数服用药物;部分的得分的刚性,动作迟缓、震颤和轴向功能; total MDS-UPDRS III; and the MDS-UPDRS part IV. Functional disability and quality of life were assessed using the MDS-UPDRS II and the PDQ39, respectively. Patient impression of change and satisfaction with the treatment were self-assessed. The Wilcoxon signed-rank test with subsequent Bonferroni's correction was used for data analysis.Results Thirty-two patients with PD were evaluated at 36 months after treatment. The mean (±SD) age at baseline was 56.0 ± 10.1 years, with a mean disease duration of 6.8 ± 2.8 years. The MDS-UPDRS III score for the treated hemibody off-medication was improved by 52.3% from baseline to 3 years (score reduction from 19.0 ± 3.2 to 8.9 ± 3.3, 95% CI 8.7 to 11.6, p < 0.001), and all specific motor features were improved from baseline. No disabling or delayed adverse events were reported. The total MDS-UPDRS III off-medication score was 22.9% lower at 3 years than before treatment (36.8 ± 7.4 vs 27.4 ± 6.2, 95% CI 6.0 to 11.5, p < 0.001). The MDS-UPDRS II, IV, and PDQ39 scores and levodopa dose were equivalent to those at baseline.Discussion The benefit of unilateral FUS-STN on PD motor features is sustained in the long term. FUS-STN contributes to better clinical control over several years of evolution. NCT02912871/03454425.Classification of Evidence This study provides Class IV evidence on the utility of focused ultrasound unilateral subthalamotomy in the treatment of people with Parkinson disease.DBS=deep brain stimulation; ET=essential tremor; FUS-STN=focused ultrasound subthalamotomy; LEDD=levodopa equivalent daily dose; MDS-UPDRS=Movement Disorder Society–Unified Parkinson's Disease Rating Scale; PD=Parkinson disease; PDQ-39SI=39-item Parkinson's Disease Questionnaire Summary Index; STN=subthalamic nucleus